David Chang
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About David Chang
David Chang is recorded as CEO at Allogene Therapeutics, Inc. (ALLO). Earlier roles on record: Board Member at Battalion Oil Corp (BATL) until March 31, 2026. Battalion Oil Corp reported in an 8-K filed April 3, 2026 that David Chang resigned as Board of Directors, effective March 31, 2026. The proxy statement of Allogene Therapeutics, Inc. reports total compensation of $4,482,208 for David Chang in fiscal 2024, including a base salary of $724,000. Disclosed compensation is on record for 7 fiscal years. David Chang has spoken on 22 earnings calls across 1 company, most recently for Allogene Therapeutics, Inc. on May 13, 2026.
“On March 30, 2026, David Chang notified the Board of Directors (the "Board") of Battalion Oil Corporation (the "Company") of his decision to resign from the Board, including from his position as Chairman of the Compensation Committee and as a member of the Reserves Committee, effective March 31, 2026.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
-
2019-01-01–2026-03-31
-
2019-01-01–2026-03-31
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Allogene Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Zachary Roberts, M.D., Ph.D. CEO, Board Member
- Geoffrey Parker CFO
- Tim Moore CTO
- Timothy Moore CTO
- Annie Yoshiyama Chief Accounting Officer
- Elizabeth Barrett Board Member
- Stephen Mayo, Ph.D. Board Member
- Vicki Sato, Ph.D. Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Allogene Therapeutics, Inc. (ALLO) | M.D., Ph.D. President and Chief Executive Officer | $724,000 | $4,482,208 |
| 2023 | Allogene Therapeutics, Inc. (ALLO) | M.D., Ph.D. President and Chief Executive Officer | $724,000 | $14,063,848 |
| 2022 | Allogene Therapeutics, Inc. (ALLO) | M.D., Ph.D. President and Chief Executive Officer | $724,000 | $14,797,837 |
| 2021 | Allogene Therapeutics, Inc. (ALLO) | M.D., Ph.D. President and Chief Executive Officer | $695,000 | $10,161,454 |
| 2020 | Allogene Therapeutics, Inc. (ALLO) | M.D., Ph.D. President and Chief Executive Officer | $675,000 | $7,815,041 |
| 2019 | Allogene Therapeutics, Inc. (ALLO) | M.D., Ph.D. President and Chief Executive Officer | $600,000 | $11,192,110 |
| 2018 | Allogene Therapeutics, Inc. (ALLO) | M.D., Ph.D. President and Chief Executive Officer | $362,413 | $12,848,537 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.